Published in Carcinogenesis on December 02, 2009
Oxidative stress, inflammation, and cancer: how are they linked? Free Radic Biol Med (2010) 7.31
Inflammation-induced cancer: crosstalk between tumours, immune cells and microorganisms. Nat Rev Cancer (2013) 4.02
Cellular senescence and the senescent secretory phenotype: therapeutic opportunities. J Clin Invest (2013) 3.47
Residual embryonic cells as precursors of a Barrett's-like metaplasia. Cell (2011) 3.36
Upsides and downsides of reactive oxygen species for cancer: the roles of reactive oxygen species in tumorigenesis, prevention, and therapy. Antioxid Redox Signal (2012) 2.05
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Mutator activity induced by microRNA-155 (miR-155) links inflammation and cancer. Proc Natl Acad Sci U S A (2011) 1.96
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
A novel miR-155/miR-143 cascade controls glycolysis by regulating hexokinase 2 in breast cancer cells. EMBO J (2012) 1.82
IL6-mediated suppression of miR-200c directs constitutive activation of inflammatory signaling circuit driving transformation and tumorigenesis. Mol Cell (2012) 1.59
Resveratrol decreases the levels of miR-155 by upregulating miR-663, a microRNA targeting JunB and JunD. Carcinogenesis (2010) 1.52
MicroRNAs and colon and rectal cancer: differential expression by tumor location and subtype. Genes Chromosomes Cancer (2010) 1.51
miRNA-26b Overexpression in Ulcerative Colitis-associated Carcinogenesis. Inflamm Bowel Dis (2015) 1.47
Specific and sensitive quantitative RT-PCR of miRNAs with DNA primers. BMC Biotechnol (2011) 1.42
Extracellular matrix remodeling: the common denominator in connective tissue diseases. Possibilities for evaluation and current understanding of the matrix as more than a passive architecture, but a key player in tissue failure. Assay Drug Dev Technol (2012) 1.30
MicroRNAs in Human Diseases: From Cancer to Cardiovascular Disease. Immune Netw (2011) 1.29
Resveratrol modulates the levels of microRNAs targeting genes encoding tumor-suppressors and effectors of TGFβ signaling pathway in SW480 cells. Biochem Pharmacol (2010) 1.28
MiRNA in innate immune responses: novel players in wound inflammation. Physiol Genomics (2010) 1.25
MicroRNA profiles discriminate among colon cancer metastasis. PLoS One (2014) 1.22
The cluster of miR-143 and miR-145 affects the risk for esophageal squamous cell carcinoma through co-regulating fascin homolog 1. PLoS One (2012) 1.22
Prostaglandin E2 EP receptors as therapeutic targets in breast cancer. Cancer Metastasis Rev (2011) 1.21
The biology of personalized cancer medicine: facing individual complexities underlying hallmark capabilities. Mol Oncol (2012) 1.21
Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol (2011) 1.19
The multiple roles of microRNA-155 in oncogenesis. J Clin Bioinforma (2013) 1.18
Translating advances from the basic biology of aging into clinical application. Exp Gerontol (2012) 1.16
Dysregulation of miR-31 and miR-21 induced by zinc deficiency promotes esophageal cancer. Carcinogenesis (2012) 1.16
A low-glycemic load diet reduces serum C-reactive protein and modestly increases adiponectin in overweight and obese adults. J Nutr (2011) 1.15
Identification of a functional SNP in the 3'UTR of CXCR2 that is associated with reduced risk of lung cancer. Cancer Res (2014) 1.14
Dietary phytochemicals and cancer prevention: Nrf2 signaling, epigenetics, and cell death mechanisms in blocking cancer initiation and progression. Pharmacol Ther (2012) 1.13
The Role of MicroRNAs in Regulatory T Cells and in the Immune Response. Immune Netw (2011) 1.13
MicroRNA expression profiling of the porcine developing brain. PLoS One (2011) 1.10
Redox metabolism and malignancy. Curr Opin Pharmacol (2010) 1.10
Environmental epigenetics and its implication on disease risk and health outcomes. ILAR J (2012) 1.10
DNA damage in inflammation-related carcinogenesis and cancer stem cells. Oxid Med Cell Longev (2013) 1.09
microRNA-99b acts as a tumor suppressor in non-small cell lung cancer by directly targeting fibroblast growth factor receptor 3. Exp Ther Med (2011) 1.07
Modeling social influences on human health. Psychosom Med (2010) 1.05
Models of carcinogenesis: an overview. Carcinogenesis (2010) 1.05
p53 and PUMA independently regulate apoptosis of intestinal epithelial cells in patients and mice with colitis. Gastroenterology (2011) 1.05
JAK inhibition alleviates the cellular senescence-associated secretory phenotype and frailty in old age. Proc Natl Acad Sci U S A (2015) 1.03
MicroRNAs in tumorigenesis, metastasis, diagnosis and prognosis of gastric cancer. Cancer Gene Ther (2015) 1.03
Genetic variation in C-reactive protein in relation to colon and rectal cancer risk and survival. Int J Cancer (2010) 1.02
A review of the anticancer potential of the antimalarial herbal cryptolepis sanguinolenta and its major alkaloid cryptolepine. Ghana Med J (2013) 1.01
Synthetic Lethal Approaches Exploiting DNA Damage in Aggressive Myeloma. Cancer Discov (2015) 1.01
Use of the ODD-luciferase transgene for the non-invasive imaging of spontaneous tumors in mice. PLoS One (2011) 1.00
High miR-21 expression from FFPE tissues is associated with poor survival and response to adjuvant chemotherapy in colon cancer. Int J Cancer (2013) 0.99
Macrophage migration inhibitory factor induces epithelial to mesenchymal transition, enhances tumor aggressiveness and predicts clinical outcome in resected pancreatic ductal adenocarcinoma. Int J Cancer (2013) 0.99
The role of prostatitis in prostate cancer: meta-analysis. PLoS One (2013) 0.98
Inflammation regulates microRNA expression in cooperation with p53 and nitric oxide. Int J Cancer (2011) 0.96
Caught in the cross fire: p53 in inflammation. Carcinogenesis (2014) 0.95
Inflammation in chronic obstructive pulmonary disease and its role in cardiovascular disease and lung cancer. Clin Transl Med (2015) 0.95
NOS2 enhances KRAS-induced lung carcinogenesis, inflammation and microRNA-21 expression. Int J Cancer (2012) 0.95
Serum metabolomics in a Helicobacter hepaticus mouse model of inflammatory bowel disease reveal important changes in the microbiome, serum peptides, and intermediary metabolism. J Proteome Res (2012) 0.95
Association of Fusobacterium species in pancreatic cancer tissues with molecular features and prognosis. Oncotarget (2015) 0.94
MicroRNA profile of circulating CD4-positive regulatory T cells in human adults and impact of differentially expressed microRNAs on expression of two genes essential to their function. J Biol Chem (2012) 0.93
Chronic inflammation and immunologic-based constraints in malignant disease. Immunotherapy (2011) 0.91
Epstein-Barr virus microRNAs and lung cancer. Br J Cancer (2011) 0.91
MicroRNAs in Human Diseases: From Autoimmune Diseases to Skin, Psychiatric and Neurodegenerative Diseases. Immune Netw (2011) 0.90
Expression of miR-486 is a potential prognostic factor after nephrectomy in advanced renal cell carcinoma. Mol Clin Oncol (2012) 0.89
Micro-RNAs in inflammatory diseases and as a link between inflammation and cancer. Inflamm Res (2013) 0.89
Intratumoral heterogeneity as a therapy resistance mechanism: role of melanoma subpopulations. Adv Pharmacol (2012) 0.89
Epigenetic determinants of ovarian clear cell carcinoma biology. Int J Cancer (2014) 0.89
Investigating prostate cancer tumour-stroma interactions: clinical and biological insights from an evolutionary game. Br J Cancer (2011) 0.88
MyD88 and its divergent toll in carcinogenesis. Trends Immunol (2013) 0.88
Host immune response to infection and cancer: unexpected commonalities. Cell Host Microbe (2014) 0.88
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Roles of the canonical myomiRs miR-1, -133 and -206 in cell development and disease. World J Biol Chem (2015) 0.87
Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis (2015) 0.86
Impairment of pre-mRNA splicing in liver disease: mechanisms and consequences. World J Gastroenterol (2010) 0.86
Nuclear morphometry, nucleomics and prostate cancer progression. Asian J Androl (2012) 0.86
Towards an understanding of the role of p53 in adrenocortical carcinogenesis. Mol Cell Endocrinol (2011) 0.86
A review of the application of inflammatory biomarkers in epidemiologic cancer research. Cancer Epidemiol Biomarkers Prev (2014) 0.86
Inflammation and MiR-21 pathways functionally interact to downregulate PDCD4 in colorectal cancer. PLoS One (2014) 0.86
RNF20 Links Histone H2B Ubiquitylation with Inflammation and Inflammation-Associated Cancer. Cell Rep (2016) 0.85
The relationship between COPD and lung cancer. Lung Cancer (2015) 0.85
Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Mol Cancer (2014) 0.85
Nitric oxide: perspectives and emerging studies of a well known cytotoxin. Int J Mol Sci (2010) 0.84
Reduced susceptibility to colitis-associated colon carcinogenesis in mice lacking plasma membrane-associated sialidase. PLoS One (2012) 0.84
The Mushroom Agaricus blazei Murill Elicits Medicinal Effects on Tumor, Infection, Allergy, and Inflammation through Its Modulation of Innate Immunity and Amelioration of Th1/Th2 Imbalance and Inflammation. Adv Pharmacol Sci (2011) 0.83
Analysis of organ-enriched microRNAs in plasma as an approach to development of Universal Screening Test: feasibility study. J Transl Med (2013) 0.83
Gene-Diet Interactions on Colorectal Cancer Risk. Curr Nutr Rep (2012) 0.83
MicroRNAs implicated in the immunopathogenesis of lupus nephritis. Clin Dev Immunol (2013) 0.83
microRNA Therapeutics in Cancer - An Emerging Concept. EBioMedicine (2016) 0.82
Piperine, a dietary phytochemical, inhibits angiogenesis. J Nutr Biochem (2012) 0.82
Microbiota modulation of myeloid cells in cancer therapy. Cancer Immunol Res (2015) 0.82
MicroRNAs: New players in cancer prevention targeting Nrf2, oxidative stress and inflammatory pathways. Curr Pharmacol Rep (2015) 0.82
Interweaving microRNAs and proinflammatory cytokines in gastric mucosa with reference to H. pylori infection. J Clin Immunol (2011) 0.82
Bacterial Lipopolysaccharides Induce Steroid Sulfatase Expression and Cell Migration through IL-6 Pathway in Human Prostate Cancer Cells. Biomol Ther (Seoul) (2012) 0.82
How do cytokines trigger genomic instability? J Biomed Biotechnol (2012) 0.82
DNA Damage and Pulmonary Hypertension. Int J Mol Sci (2016) 0.81
Targeting aldose reductase for the treatment of cancer. Curr Cancer Drug Targets (2011) 0.81
Reciprocal control of miR-197 and IL-6/STAT3 pathway reveals miR-197 as potential therapeutic target for hepatocellular carcinoma. Oncoimmunology (2015) 0.81
Effect of novel marine nutraceuticals on IL-1α-mediated TNF-α release from UVB-irradiated human melanocyte-derived cells. Oxid Med Cell Longev (2011) 0.81
MicroRNA-221 promotes human non-small cell lung cancer cell H460 growth. Int J Clin Exp Med (2015) 0.81
Synergistic anti-inflammatory effects of nobiletin and sulforaphane in lipopolysaccharide-stimulated RAW 264.7 cells. J Agric Food Chem (2012) 0.81
Cellular Senescence and the Biology of Aging, Disease, and Frailty. Nestle Nutr Inst Workshop Ser (2015) 0.80
Involvement of free radicals in breast cancer. Springerplus (2013) 0.80
The transient and constitutive inflammatory signaling in tumorigenesis. Cell Cycle (2012) 0.80
MicroRNA-155 broadly orchestrates inflammation-induced changes of microRNA expression in breast cancer. Cell Res (2013) 0.80
Regulation of Metabolic Activity by p53. Metabolites (2017) 0.79
Dietary diindolylmethane suppresses inflammation-driven lung squamous cell carcinoma in mice. Cancer Prev Res (Phila) (2014) 0.79
MicroRNA expression profiles classify human cancers. Nature (2005) 69.12
A microRNA polycistron as a potential human oncogene. Nature (2005) 40.21
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Cancer-related inflammation. Nature (2008) 34.21
Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans. Cell (1993) 33.79
Circulating microRNAs as stable blood-based markers for cancer detection. Proc Natl Acad Sci U S A (2008) 33.65
Silencing of microRNAs in vivo with 'antagomirs'. Nature (2005) 32.56
The impact of microRNAs on protein output. Nature (2008) 32.39
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Widespread changes in protein synthesis induced by microRNAs. Nature (2008) 31.44
RAS is regulated by the let-7 microRNA family. Cell (2005) 30.24
Human microRNA genes are frequently located at fragile sites and genomic regions involved in cancers. Proc Natl Acad Sci U S A (2004) 28.29
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med (2005) 26.02
Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 24.54
Helicobacter pylori infection and the risk of gastric carcinoma. N Engl J Med (1991) 23.89
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
Diffuse pleural mesothelioma and asbestos exposure in the North Western Cape Province. Br J Ind Med (1960) 23.03
ras oncogenes in human cancer: a review. Cancer Res (1989) 22.03
NF-kappaB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proc Natl Acad Sci U S A (2006) 21.58
Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases. Cell Res (2008) 20.59
Conservation of the sequence and temporal expression of let-7 heterochronic regulatory RNA. Nature (2000) 19.15
Reduced expression of the let-7 microRNAs in human lung cancers in association with shortened postoperative survival. Cancer Res (2004) 18.86
MicroRNA-21 is an antiapoptotic factor in human glioblastoma cells. Cancer Res (2005) 18.58
IKKbeta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell (2004) 15.82
NF-kappaB functions as a tumour promoter in inflammation-associated cancer. Nature (2004) 15.14
MicroRNA profiling reveals distinct signatures in B cell chronic lymphocytic leukemias. Proc Natl Acad Sci U S A (2004) 14.59
MicroRNA-21 regulates expression of the PTEN tumor suppressor gene in human hepatocellular cancer. Gastroenterology (2007) 13.20
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Origin and physiological roles of inflammation. Nature (2008) 11.68
IL-6 and Stat3 are required for survival of intestinal epithelial cells and development of colitis-associated cancer. Cancer Cell (2009) 11.52
LNA-mediated microRNA silencing in non-human primates. Nature (2008) 11.45
MicroRNA-155 is induced during the macrophage inflammatory response. Proc Natl Acad Sci U S A (2007) 11.42
Therapeutic microRNA delivery suppresses tumorigenesis in a murine liver cancer model. Cell (2009) 11.10
Pre-B cell proliferation and lymphoblastic leukemia/high-grade lymphoma in E(mu)-miR155 transgenic mice. Proc Natl Acad Sci U S A (2006) 10.65
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
miR-21-mediated tumor growth. Oncogene (2006) 9.90
A randomized trial of aspirin to prevent colorectal adenomas. N Engl J Med (2003) 9.18
Differential expression of microRNAs in plasma of patients with colorectal cancer: a potential marker for colorectal cancer screening. Gut (2009) 8.98
Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology (1994) 8.79
Modulation of miR-155 and miR-125b levels following lipopolysaccharide/TNF-alpha stimulation and their possible roles in regulating the response to endotoxin shock. J Immunol (2007) 8.05
Enterocolitis and colon cancer in interleukin-10-deficient mice are associated with aberrant cytokine production and CD4(+) TH1-like responses. J Clin Invest (1996) 7.97
Modulation of microRNA processing by p53. Nature (2009) 7.88
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. Carcinogenesis (2009) 7.55
Augmentation of tumor angiogenesis by a Myc-activated microRNA cluster. Nat Genet (2006) 7.53
Programmed cell death 4 (PDCD4) is an important functional target of the microRNA miR-21 in breast cancer cells. J Biol Chem (2007) 7.46
The interleukin-8 pathway in cancer. Clin Cancer Res (2008) 7.12
A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med (2003) 6.99
Aspirin use and survival after diagnosis of colorectal cancer. JAMA (2009) 6.93
MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1). J Biol Chem (2007) 6.88
Ulcerative colitis and colorectal cancer. A population-based study. N Engl J Med (1990) 6.87
Tumour necrosis factor and cancer. Nat Rev Cancer (2009) 6.27
Cell transformation by the superoxide-generating oxidase Mox1. Nature (1999) 6.23
MicroRNA expression, survival, and response to interferon in liver cancer. N Engl J Med (2009) 6.13
miR-21: a small multi-faceted RNA. J Cell Mol Med (2009) 5.59
ROS-generating mitochondrial DNA mutations can regulate tumor cell metastasis. Science (2008) 5.54
MicroRNA expression profiles in serous ovarian carcinoma. Clin Cancer Res (2008) 5.54
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
Association of macrophage infiltration with angiogenesis and prognosis in invasive breast carcinoma. Cancer Res (1996) 5.38
Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med (1993) 5.32
Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc Natl Acad Sci U S A (2008) 5.29
Microsatellite instability and mutations of the transforming growth factor beta type II receptor gene in colorectal cancer. Cancer Res (1995) 5.26
Cancer immunology. N Engl J Med (2008) 5.22
Interleukin-6 dependent survival of multiple myeloma cells involves the Stat3-mediated induction of microRNA-21 through a highly conserved enhancer. Blood (2007) 5.14
Exosomal microRNA: a diagnostic marker for lung cancer. Clin Lung Cancer (2009) 5.11
NF-kappaB is essential for epithelial-mesenchymal transition and metastasis in a model of breast cancer progression. J Clin Invest (2004) 5.06
Aspirin and non-steroidal anti-inflammatory drugs for cancer prevention: an international consensus statement. Lancet Oncol (2009) 5.05
A SNP in a let-7 microRNA complementary site in the KRAS 3' untranslated region increases non-small cell lung cancer risk. Cancer Res (2008) 5.05
The let-7 microRNA reduces tumor growth in mouse models of lung cancer. Cell Cycle (2008) 4.95
Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer (2001) 4.62
DNA methylation and cancer. J Clin Oncol (2004) 4.58
Identification of metastasis-related microRNAs in hepatocellular carcinoma. Hepatology (2008) 4.50
Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. Cancer Cell (2006) 4.33
Oncogenic Ras-induced secretion of IL6 is required for tumorigenesis. Genes Dev (2007) 4.25
Ras-induced interleukin-8 expression plays a critical role in tumor growth and angiogenesis. Cancer Cell (2004) 4.23
Hereditary pancreatitis and the risk of pancreatic cancer. International Hereditary Pancreatitis Study Group. J Natl Cancer Inst (1997) 4.23
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform. Gynecol Oncol (2008) 4.10
Tumor protein 53-induced nuclear protein 1 expression is repressed by miR-155, and its restoration inhibits pancreatic tumor development. Proc Natl Acad Sci U S A (2007) 4.04
NF-kappaB promotes breast cancer cell migration and metastasis by inducing the expression of the chemokine receptor CXCR4. J Biol Chem (2003) 3.98
MicroRNAs: novel regulators involved in the pathogenesis of psoriasis? PLoS One (2007) 3.96
Interleukin-10: new perspectives on an old cytokine. Immunol Rev (2008) 3.94
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Genetic variants of miRNA sequences and non-small cell lung cancer survival. J Clin Invest (2008) 3.53
Expression of microRNA-146 in rheumatoid arthritis synovial tissue. Arthritis Rheum (2008) 3.35
MicroRNAs are differentially expressed in ulcerative colitis and alter expression of macrophage inflammatory peptide-2 alpha. Gastroenterology (2008) 3.29
miR-155 gene: a typical multifunctional microRNA. Biochim Biophys Acta (2009) 3.28
Induction and regulatory function of miR-9 in human monocytes and neutrophils exposed to proinflammatory signals. Proc Natl Acad Sci U S A (2009) 3.27
DNA damage induced by chronic inflammation contributes to colon carcinogenesis in mice. J Clin Invest (2008) 3.17
Psoriasis. Lancet (2003) 3.05
Inducible nitric oxide synthase binds, S-nitrosylates, and activates cyclooxygenase-2. Science (2005) 3.05
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
Daily soluble aspirin and prevention of colorectal adenoma recurrence: one-year results of the APACC trial. Gastroenterology (2003) 2.96
Rapid changes in microRNA-146a expression negatively regulate the IL-1beta-induced inflammatory response in human lung alveolar epithelial cells. J Immunol (2008) 2.95
Tumour immunity: effector response to tumour and role of the microenvironment. Lancet (2008) 2.94
Inflammation: gearing the journey to cancer. Mutat Res (2008) 2.89
MicroRNA-21 is up-regulated in allergic airway inflammation and regulates IL-12p35 expression. J Immunol (2009) 2.89
Cytokines and their relationship to the symptoms and outcome of cancer. Nat Rev Cancer (2008) 2.89
A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A (2006) 40.09
Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer Cell (2006) 23.59
The IARC TP53 database: new online mutation analysis and recommendations to users. Hum Mutat (2002) 12.39
MicroRNA expression profiles associated with prognosis and therapeutic outcome in colon adenocarcinoma. JAMA (2008) 12.26
Genetic variation in microRNA networks: the implications for cancer research. Nat Rev Cancer (2010) 7.39
Radical causes of cancer. Nat Rev Cancer (2003) 5.45
KIF5B-RET fusions in lung adenocarcinoma. Nat Med (2012) 4.38
Inflammation and cancer: an ancient link with novel potentials. Int J Cancer (2007) 4.19
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
MiR-21 is an EGFR-regulated anti-apoptotic factor in lung cancer in never-smokers. Proc Natl Acad Sci U S A (2009) 3.64
Genetic variants and risk of lung cancer in never smokers: a genome-wide association study. Lancet Oncol (2010) 3.49
The landscape of recombination in African Americans. Nature (2011) 3.06
MicroRNA expression in squamous cell carcinoma and adenocarcinoma of the esophagus: associations with survival. Clin Cancer Res (2009) 3.03
p53: traffic cop at the crossroads of DNA repair and recombination. Nat Rev Mol Cell Biol (2005) 2.78
The chemical biology of nitric oxide: implications in cellular signaling. Free Radic Biol Med (2008) 2.72
Reprogramming of miRNA networks in cancer and leukemia. Genome Res (2010) 2.65
Increased levels of circulating interleukin 6, interleukin 8, C-reactive protein, and risk of lung cancer. J Natl Cancer Inst (2011) 2.61
Circulating plasma MiR-141 is a novel biomarker for metastatic colon cancer and predicts poor prognosis. PLoS One (2011) 2.57
p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol (2009) 2.46
Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res (2008) 2.45
p29ING4 and p28ING5 bind to p53 and p300, and enhance p53 activity. Cancer Res (2003) 2.40
Dominant role of hepatitis B virus and cofactor role of aflatoxin in hepatocarcinogenesis in Qidong, China. Hepatology (2002) 2.38
TP53 mutation spectra and load: a tool for generating hypotheses on the etiology of cancer. IARC Sci Publ (2004) 2.23
TP53 and liver carcinogenesis. Hum Mutat (2003) 2.23
p53-induced up-regulation of MnSOD and GPx but not catalase increases oxidative stress and apoptosis. Cancer Res (2004) 2.08
p53-Repressed miRNAs are involved with E2F in a feed-forward loop promoting proliferation. Mol Syst Biol (2008) 2.04
Nitric oxide-induced cellular stress and p53 activation in chronic inflammation. Proc Natl Acad Sci U S A (2002) 2.04
BLM heterozygosity and the risk of colorectal cancer. Science (2002) 2.03
Circulating micro-RNA expression profiles in early stage nonsmall cell lung cancer. Int J Cancer (2011) 2.02
Regulation of cyclooxygenase-2 expression by the Wnt and ras pathways. Cancer Res (2003) 1.97
Ionizing radiation-induced oxidative stress alters miRNA expression. PLoS One (2009) 1.94
CSF biomarker variability in the Alzheimer's Association quality control program. Alzheimers Dement (2013) 1.90
MicroRNA expression and clinical outcomes in patients treated with adjuvant chemotherapy after complete resection of non-small cell lung carcinoma. Cancer Res (2010) 1.89
Hypoxic inducible factor 1alpha, extracellular signal-regulated kinase, and p53 are regulated by distinct threshold concentrations of nitric oxide. Proc Natl Acad Sci U S A (2004) 1.87
Transcriptional programs following genetic alterations in p53, INK4A, and H-Ras genes along defined stages of malignant transformation. Cancer Res (2005) 1.86
Mutant p53 prolongs NF-κB activation and promotes chronic inflammation and inflammation-associated colorectal cancer. Cancer Cell (2013) 1.86
Advances in chemical carcinogenesis: a historical review and prospective. Cancer Res (2008) 1.83
A meta-analysis identifies new loci associated with body mass index in individuals of African ancestry. Nat Genet (2013) 1.82
Functional interaction between BLM helicase and 53BP1 in a Chk1-mediated pathway during S-phase arrest. J Cell Biol (2004) 1.82
The adaptive imbalance in base excision-repair enzymes generates microsatellite instability in chronic inflammation. J Clin Invest (2003) 1.82
MicroRNAs in liver disease. Gastroenterology (2012) 1.76
POT1 and TRF2 cooperate to maintain telomeric integrity. Mol Cell Biol (2005) 1.74
BLM helicase-dependent transport of p53 to sites of stalled DNA replication forks modulates homologous recombination. EMBO J (2003) 1.71
Mutations in the tyrosine kinase domain of the epidermal growth factor receptor in non-small cell lung cancer. Clin Cancer Res (2005) 1.70
Inflammation-mediated genetic and epigenetic alterations drive cancer development in the neighboring epithelium upon stromal abrogation of TGF-β signaling. PLoS Genet (2013) 1.69
Association of inflammation-related and microRNA gene expression with cancer-specific mortality of colon adenocarcinoma. Clin Cancer Res (2009) 1.67
Microenvironmental modulation of asymmetric cell division in human lung cancer cells. Proc Natl Acad Sci U S A (2010) 1.66
Prolonged culture of telomerase-immortalized human fibroblasts leads to a premalignant phenotype. Cancer Res (2003) 1.64
Clinical outcomes and correlates of TP53 mutations and cancer. Cold Spring Harb Perspect Biol (2010) 1.64
The rectal cancer microRNAome--microRNA expression in rectal cancer and matched normal mucosa. Clin Cancer Res (2012) 1.61
Aurora-A/STK15 T+91A is a general low penetrance cancer susceptibility gene: a meta-analysis of multiple cancer types. Carcinogenesis (2005) 1.61
Use of a cytokine gene expression signature in lung adenocarcinoma and the surrounding tissue as a prognostic classifier. J Natl Cancer Inst (2007) 1.58
Laser capture microdissection and microarray expression analysis of lung adenocarcinoma reveals tobacco smoking- and prognosis-related molecular profiles. Cancer Res (2002) 1.53
Genetically reduced antioxidative protection and increased ischemic heart disease risk: The Copenhagen City Heart Study. Circulation (2003) 1.52
p53: 25 years after its discovery. Trends Pharmacol Sci (2004) 1.49
Quantification of cleaved beta2-microglobulin in serum from patients undergoing chronic hemodialysis. Clin Chem (2005) 1.49
Telomere recombination requires the MUS81 endonuclease. Nat Cell Biol (2009) 1.45
Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3'-kinase/Akt pathway in vitro and in vivo. Cancer Res (2004) 1.45
Laser capture microdissection and protein microarray analysis of human non-small cell lung cancer: differential epidermal growth factor receptor (EGPR) phosphorylation events associated with mutated EGFR compared with wild type. Mol Cell Proteomics (2008) 1.44
Lung cancer in never smokers: molecular profiles and therapeutic implications. Clin Cancer Res (2009) 1.44
The role of microRNAs in colorectal cancer. Cancer J (2012) 1.44
The p53 tumor suppressor network is a key responder to microenvironmental components of chronic inflammatory stress. Cancer Res (2005) 1.42
A novel PHD-finger motif protein, p47ING3, modulates p53-mediated transcription, cell cycle control, and apoptosis. Oncogene (2003) 1.40
WNT16B is a new marker of cellular senescence that regulates p53 activity and the phosphoinositide 3-kinase/AKT pathway. Cancer Res (2009) 1.39
Exploring the sialiome using titanium dioxide chromatography and mass spectrometry. Mol Cell Proteomics (2007) 1.38
Molecular pathogenesis of human hepatocellular carcinoma. Toxicology (2002) 1.35
p53 functions in the incorporation step in DNA base excision repair in mouse liver mitochondria. Oncogene (2004) 1.33
p53 interacts with hRAD51 and hRAD54, and directly modulates homologous recombination. Cancer Res (2003) 1.32
ING2 regulates the onset of replicative senescence by induction of p300-dependent p53 acetylation. Mol Cell Biol (2005) 1.31
Bleomycin-induced chromosome breaks as a risk marker for lung cancer: a case-control study with population and hospital controls. Carcinogenesis (2003) 1.31
The association of microRNA expression with prognosis and progression in early-stage, non-small cell lung adenocarcinoma: a retrospective analysis of three cohorts. Clin Cancer Res (2011) 1.29
Nitric oxide in cancer and chemoprevention. Free Radic Biol Med (2003) 1.29
Novel splice variants of ING4 and their possible roles in the regulation of cell growth and motility. J Biol Chem (2006) 1.28
Association of TP53 mutations with stem cell-like gene expression and survival of patients with hepatocellular carcinoma. Gastroenterology (2010) 1.28
Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis Rheum (2013) 1.28
Tumor suppressor miR-22 determines p53-dependent cellular fate through post-transcriptional regulation of p21. Cancer Res (2011) 1.27
Arachidonate lipoxygenase (ALOX) and cyclooxygenase (COX) polymorphisms and colon cancer risk. Carcinogenesis (2004) 1.25
ING1 represses transcription by direct DNA binding and through effects on p53. Cancer Res (2003) 1.25
Increased IgG on cell-derived plasma microparticles in systemic lupus erythematosus is associated with autoantibodies and complement activation. Arthritis Rheum (2012) 1.25
Sample handling for mass spectrometric proteomic investigations of human sera. Anal Chem (2005) 1.23
Exploring SNP-SNP interactions and colon cancer risk using polymorphism interaction analysis. Int J Cancer (2006) 1.23
The processing of Holliday junctions by BLM and WRN helicases is regulated by p53. J Biol Chem (2002) 1.22
Superoxide fluxes limit nitric oxide-induced signaling. J Biol Chem (2006) 1.22
Detection of HPV DNA in esophageal cancer specimens from different regions and ethnic groups: a descriptive study. BMC Cancer (2010) 1.22
p53 isoforms regulate aging- and tumor-associated replicative senescence in T lymphocytes. J Clin Invest (2013) 1.21
Identification of carboxypeptidase E and gamma-glutamyl hydrolase as biomarkers for pulmonary neuroendocrine tumors by cDNA microarray. Hum Pathol (2004) 1.20
Nitric oxide is a key component in inflammation-accelerated tumorigenesis. Cancer Res (2008) 1.19
Inhibitor of growth 4 suppresses cell spreading and cell migration by interacting with a novel binding partner, liprin alpha1. Cancer Res (2007) 1.19
Alterations of microRNAs contribute to colon carcinogenesis. Semin Oncol (2011) 1.19
Increased miR-708 expression in NSCLC and its association with poor survival in lung adenocarcinoma from never smokers. Clin Cancer Res (2012) 1.18
Nitric oxide, a mediator of inflammation, suppresses tumorigenesis. Cancer Res (2004) 1.15
Olfactomedin 4 defines a subset of human neutrophils. J Leukoc Biol (2011) 1.15
Positive feedback between p53 and TRF2 during telomere-damage signalling and cellular senescence. Nat Cell Biol (2010) 1.14
Chronic epithelial NF-κB activation accelerates APC loss and intestinal tumor initiation through iNOS up-regulation. Proc Natl Acad Sci U S A (2012) 1.13
The role of p53 in base excision repair following genotoxic stress. Carcinogenesis (2003) 1.13
Distinct features of circulating microparticles and their relationship to clinical manifestations in systemic lupus erythematosus. Arthritis Rheum (2011) 1.13
Macrophage-dependent nitric oxide expression regulates tumor cell detachment and metastasis after IL-2/anti-CD40 immunotherapy. J Exp Med (2010) 1.12
Nitric oxide and p53 in cancer-prone chronic inflammation and oxyradical overload disease. Environ Mol Mutagen (2004) 1.12